REDWOOD CITY, Calif.,
May 22, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that Vince Angotti, Chief Executive Officer, will be
presenting and taking 1x1 meetings at the Jefferies 2018 Global
Healthcare Conference.
Details of the event are as follows:
Jefferies 2018 Global Healthcare Conference
Date: Wednesday, June 6, 2018
Location: Grand Hyatt Hotel, New
York
Presentation Time: 8:00 am ET,
5:00 am PT
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO™ outside the United States, with a proposed indication
for the treatment of moderate-to-severe acute pain in medically
supervised settings, and Zalviso® (sufentanil sublingual tablet
system, 15 mcg) being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in hospitalized patients.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-jefferies-2018-global-healthcare-conference-300652846.html
SOURCE AcelRx Pharmaceuticals, Inc.